Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice

[1]  Y. Mizutani,et al.  Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo , 2003, Gene Therapy.

[2]  J. Hilliard,et al.  Characterization of B virus glycoprotein antibodies induced by DNA immunization , 2002, Archives of Virology.

[3]  O. Mazda,et al.  Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors. , 2002, Current gene therapy.

[4]  Leaf Huang,et al.  Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. , 2002, Human gene therapy.

[5]  S. Ohashi,et al.  Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein–Barr virus (EBV)-based plasmid vectors , 2001, Gene Therapy.

[6]  H. Hirai,et al.  In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice , 2001, Gene Therapy.

[7]  M. Kay,et al.  Epstein–Barr Virus/Human Vector Provides High-Level, Long-Term Expression of α1-Antitrypsin in Mice , 2001 .

[8]  M. Kay,et al.  Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  R. Manservigi,et al.  Mice Genetic Immunization with Plasmid DNA Encoding a Secreted Form of HSV-1 gB Induces a Protective Immune Response against Herpes simplex Virus Type 1 Infection , 2001, Intervirology.

[10]  O. Mazda,et al.  Direct intra-cardiomuscular transfer of β2-adrenergic receptor gene augments cardiac output in cardiomyopathic hamsters , 2000, Gene Therapy.

[11]  H. Chiou,et al.  Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver. , 2000, Vaccine.

[12]  D. Bernstein,et al.  Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. , 1999, Vaccine.

[13]  J. Wolff,et al.  High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. , 1999, Human gene therapy.

[14]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[15]  J. Kim,et al.  IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. , 1999, Journal of immunology.

[16]  D. Weiner,et al.  In Vivo Modulation of Vaccine-Induced Immune Responses toward a Th1 Phenotype Increases Potency and Vaccine Effectiveness in a Herpes Simplex Virus Type 2 Mouse Model , 1999, Journal of Virology.

[17]  A. Cunningham,et al.  Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. , 1998, The Journal of general virology.

[18]  E. Raz,et al.  Gene vaccination: plasmid DNA is more than just a blueprint. , 1998, Immunology today.

[19]  A. Nesburn,et al.  The importance of MHC‐I and MHC‐II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge , 1997, Immunology.

[20]  O. Mazda,et al.  Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. , 1997, Journal of immunological methods.

[21]  B. Rouse,et al.  Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization , 1997, Journal of virology.

[22]  E. Kremmer,et al.  Epstein-Barr Virus Nuclear Antigen 1 Forms a Complex with the Nuclear Transporter Karyopherin α2* , 1997, The Journal of Biological Chemistry.

[23]  J. Wands,et al.  Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. , 1997, Journal of immunology.

[24]  B. Rouse,et al.  Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells , 1997, Journal of leukocyte biology.

[25]  R. D. Keys,et al.  Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Epler,et al.  Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein. , 1996, Virology.

[27]  D. Bernstein,et al.  DNA immunization against experimental genital herpes simplex virus infection. , 1996, The Journal of infectious diseases.

[28]  R. Daynes,et al.  Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. , 1996, The Journal of infectious diseases.

[29]  J. Reimann,et al.  DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. , 1995, Human gene therapy.

[30]  A. Nesburn,et al.  Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. , 1995, Antiviral research.

[31]  F. Carbone,et al.  Characterization of diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential V beta bias , 1995, Journal of virology.

[32]  B. Rouse,et al.  Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. , 1995, Journal of immunology.

[33]  R. Welsh,et al.  Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. , 1995, Journal of immunology.

[34]  M. Yokoyama,et al.  DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection , 1995, Journal of virology.

[35]  B. Sugden,et al.  An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene , 1995, Journal of virology.

[36]  R. Chervenak,et al.  Analysis of the cytolytic T-lymphocyte response to herpes simplex virus type 1 glycoprotein B during primary and secondary infection , 1994, Journal of virology.

[37]  D. Fuller,et al.  A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. , 1994, AIDS research and human retroviruses.

[38]  E. Raz,et al.  Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Rouse,et al.  Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins , 1994, Journal of virology.

[40]  R. Eisenberg,et al.  Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions , 1994, Journal of virology.

[41]  A. Nesburn,et al.  Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice , 1994, Journal of virology.

[42]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[43]  J. W. Bodnar,et al.  A nuclear matrix attachment region organizes the Epstein‐Barr viral plasmid in Raji cells into a single DNA domain. , 1992, The EMBO journal.

[44]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[45]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[46]  L. Corey,et al.  Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. , 1991, The Journal of infectious diseases.

[47]  G. Hayward,et al.  Functional domains of Epstein-Barr virus nuclear antigen EBNA-1 , 1991, Journal of virology.

[48]  F. Graham,et al.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides , 1991, Journal of virology.

[49]  S. Bolling,et al.  Expression of recombinant genes in myocardium in vivo after direct injection of DNA. , 1990, Circulation.

[50]  P. Spear,et al.  Herpes simplex virus glycoprotein D is recognized as antigen by CD4+ and CD8+ T lymphocytes from infected mice. Characterization of T cell clones. , 1990, Journal of immunology.

[51]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[52]  J. Yates,et al.  Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus , 1989, Journal of virology.

[53]  浅田 秀基.  Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL) -12 and IL-18 by means of the EBV/lipoplex , 2004 .

[54]  田中 斉祐,et al.  Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter , 2002 .

[55]  M. Kay,et al.  Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  田畑 博子.  Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer , 2000 .

[57]  A. García-Carrancá,et al.  Viral vectors : basic science and gene therapy , 2000 .

[58]  D. Bernstein,et al.  Herpes simplex virus vaccines. , 1999, Vaccine.

[59]  佐藤 悦子.  Successful transfer of ADA gene in vitro into human peripheral blood CD34[+] cells by transfecting EBV-based episomal vectors , 1999 .

[60]  原田 義規.  Highly efficient suicide gene expression in hepatocellular carcinoma cells by Epstein-Barr Virus-based plasmid vectors combined with polyamidoamine dendrimer , 1999 .

[61]  B. Rouse,et al.  DNA vaccines and immunity to herpes simplex virus. , 1998, Current topics in microbiology and immunology.

[62]  J. Imanishi,et al.  Induction de l'ARN messager des cytokines par l'infection de l'Herpès simplex virus chez la souris. , 1993 .

[63]  R. Burke.  Contemporary approaches to vaccination against herpes simplex virus. , 1992, Current topics in microbiology and immunology.

[64]  J. Yates,et al.  Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.